Success Story: Without Any RFE Issues! Our Expert Team Helped a Graduate Student From Serbia Secure Success Smoothly
Client’s Testimonial:
“Everyone I’ve interacted with was super helpful. Thank you all for your hard work!”
On November 18th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Graduate Student in the Field of Biomedical Science (Approval Notice).
General Field: Biomedical Science
Position at the Time of Case Filing: Graduate Student
Country of Origin: Serbia
Approval Notice Date: November 18th, 2025
Processing Time: 21 months, 20 days
Case Summary:
North America Immigration Law Group (NAILG) is proud to share the approval of an EB-2 National Interest Waiver petition for a biomedical science researcher whose work addresses a rapidly growing national health threat: antibiotic-resistant bacterial infections. The client holds a B.S. in Mathematics and Biology and currently works in a U.S.-based biomedical research role, continuing research that merges experimental microbiology with advanced modeling to support new therapeutic discovery.
What the Client Is Working On
The client’s proposed endeavor is to develop a novel experimental and modeling framework for identifying new drug targets and therapeutic strategies to combat antibiotic-resistant bacteria. This approach integrates large-scale biological data, bioinformatics pipelines, and mathematical models of antibiotic response dynamics. The goal is to uncover pathways that drive resistance and reveal actionable targets that can guide next-generation treatment development.
Why This Work Matters to the United States
Drug-resistant infections pose a severe and escalating burden on U.S. healthcare, with millions of cases annually and tens of thousands of deaths. In the petition, NAILG demonstrated that the client’s endeavor supports urgent national priorities, including expanding the pipeline of effective antibiotics, strengthening public health resilience, and advancing critical emerging technologies such as bioinformatics and predictive modeling. This work aligns directly with national strategies aimed at reducing antimicrobial resistance and protecting U.S. public welfare.
Key Credentials We Highlighted
To show the client is well-positioned to advance this nationally important endeavor, we presented a strong record of research productivity and growing influence:
- 12 peer-reviewed journal articles (including 1 first-authored)
- 8 abstracts (with 5 first-authored)
- 1 first-authored preprint
- 28 citations demonstrating early but meaningful uptake by independent researchers
- At least 1 completed peer review confirming recognition as a trusted evaluator
Even with a modest citation count relative to senior researchers, the petition showed that several of the client’s most impactful papers already rank among the highly cited works in biology and biochemistry for their publication years, highlighting exceptional relevance and scientific significance within the field.
Recommendation Letters
To reinforce impact and future value, NAILG submitted four expert recommendation letters, including independent advisory opinions. These letters confirmed that the client’s modeling frameworks and experimental approaches offer rare value in uncovering resistance pathways and therapeutic targets.
“Her studies are imperative for long-term progress and growth in the medical industry and her many original findings have elevated her status as one of the top experts in her field today. She is therefore more than deserving of retention by the U.S.”
NIW Approval and Outlook
USCIS approved the NIW petition after recognizing both the national urgency of antibiotic-resistance research and the client’s demonstrated ability to advance this work in the United States. The approval allows the client to continue developing integrated experimental and computational tools that support new therapies, protect public health, and strengthen U.S. scientific leadership. NAILG is honored to have guided this case to success and looks forward to the client’s continued contributions to biomedical innovation and antimicrobial resistance solutions in the years ahead.

